Did FDA's Pain Med Warning Scare Shionogi Away From Victory?
This article was originally published in PharmAsia News
Executive Summary
Has Victory been turned into defeat? The abrupt and mysterious evaporation of Shionogi's plans to buy Victory Pharma for $150 million is fueling speculation that Japanese pharma got cold feet about the deal, possibly because of FDA's shifting policy on pain products
You may also be interested in...
Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say
TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas
Shionogi Success As Global Player May Hinge on Obesity Drug In U.S., Analysts Say
TOKYO - In a bid to be recognized as a global player, mid-size pharmacuetical outfit Shionogi & Co. has been preparing to launch a few new drugs, including the anti-obesity drug S-2367 (velneperit), but analysts say it's too early to determine whether Shionogi can be successful overseas
Deals Shaping the Medical Industry (06/2009)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.